<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />



<meta name="date" content="2026-02-13" />

<title>BALAMINES</title>

<script src="rmdlib/header-attrs-2.30/header-attrs.js"></script>
<script src="rmdlib/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="rmdlib/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="rmdlib/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="rmdlib/navigation-1.1/tabsets.js"></script>
<script src="rmdlib/accessible-code-block-0.0.1/empty-anchor.js"></script>
<link href="rmdlib/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="rmdlib/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />
<meta name="description" content="Indian equities analysis, margin reports, risk, etc..." />
<meta property="og:image" content="https://avatars3.githubusercontent.com/u/21966469?s=400&v=4" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>










<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">StockViz</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-globe"></span>
     
    Macro
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-bnd.html">Fixed Income</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cur.html">Currencies</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cmdy.html">Commodities</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-arrows-v"></span>
     
    52w H&amp;L
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-rocket"></span>
     
    ATH
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-magnet"></span>
     
    Drawdowns
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-train"></span>
     
    Streaks
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-hand-pointer-o"></span>
     
    Indian Indices
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-risk.html">Performance Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-IN.html">Index Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-MKT-CAP.html">Classification Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-industry.html">Industry Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-syn.html">Synthetic Indices</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-vol-NIFTY.html">NIFTY Volatility</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-valuations.html">Valuations</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/results-IN.html">Result Dates</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/eq-in/rp-margin.html">Margin Report</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-shopping-bag"></span>
     
    Funds
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports03/mf/rp-IN.html">Indian Mutual Funds</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports03/pms/rp-IN.html">Indian PMS</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-risk.html">US ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-sector.html">US Sector ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-country.html">Country $ ETFs</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-percent"></span>
     
    Fama-French
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-industry.html">Industry</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-factors.html">Factors</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-regression.html">Regressions</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https://stockviz.biz">
    <span class="fa fa-home"></span>
     
  </a>
</li>
<li>
  <a href="https://stockviz.substack.com">
    <span class="fa fa-envelope-o"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">BALAMINES</h1>
<h3 class="subtitle">Equity Metrics</h3>
<h4 class="date">February 13, 2026</h4>

</div>


<div id="balaji-amines-limited" class="section level1">
<h1>Balaji Amines Limited</h1>
<p><a href="/reports01/index/industry/rp-SpecialtyChemicals.html">Specialty Chemicals</a></p>
<div id="annual-returns" class="section level2">
<h2>Annual Returns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.BALAMINES.fan.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.BALAMINES.annret.png" /></p>
</div>
<div id="cumulative-returns-and-drawdowns" class="section level2">
<h2>Cumulative Returns and Drawdowns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.BALAMINES.cumret.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.BALAMINES.sma.cumret.png" /></p>
<p><br><br></p>
</div>
<div id="fundamentals" class="section level2">
<h2>Fundamentals</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.BALAMINES.eps.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.BALAMINES.RevenueFromOperations.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.BALAMINES.ebit.png" /></p>
<p><br><br></p>
</div>
<div id="ownership" class="section level2">
<h2>Ownership</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.BALAMINES.ownership.png" /></p>
<p><br><br></p>
</div>
<div id="margined" class="section level2">
<h2>Margined</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.BALAMINES.mtf.png" /></p>
<p><br><br></p>
<p><br />
</p>
</div>
<div id="ai-summary" class="section level2">
<h2>AI Summary</h2>
<p><em>asof: 2025-12-08 </em></p>
<p>Based on a comprehensive analysis of <strong>Balaji Amines Limited‚Äôs (BALAMINES, Scrip Code: 530999)</strong> investor presentation, financial releases, regulatory filings, and corporate announcements dated between <strong>September and November 2025</strong>, the following is a detailed summary of the company‚Äôs <strong>headwinds, tailwinds, growth prospects, and key risks</strong>.</p>
<hr />
<div id="company-overview-quick-snapshot" class="section level9">
<p class="heading">üîç <strong>Company Overview (Quick Snapshot)</strong></p>
<ul>
<li><strong>Founded:</strong> 1988</li>
<li><strong>Core Business:</strong> Manufacturing of <strong>Aliphatic Amines</strong> (Methylamines, Ethylamines), <strong>Amine Derivatives</strong>, and <strong>Specialty Chemicals</strong></li>
<li><strong>Key Segments:</strong> Pharma (51%), Agrochemicals (26%), Paints &amp; Resins, Animal Feed, Oil &amp; Gas, etc.</li>
<li><strong>Manufacturing:</strong> 4 facilities ‚Äì 3 in <strong>Solapur, Maharashtra</strong>, 1 near <strong>Hyderabad, Telangana</strong></li>
<li><strong>Subsidiary:</strong> Balaji Specialty Chemicals Ltd (BSCL) ‚Äì 55% owned, with mega expansion underway</li>
<li><strong>Hotel Venture:</strong> Balaji Sarovar Premiere, a 5-star hotel in Solapur (non-core business, ~2.3% revenue)</li>
<li><strong>Market Position:</strong>
<ul>
<li><strong>Largest manufacturer of Aliphatic Amines in India</strong><br />
</li>
<li><strong>Market leader in Methylamines (48,000‚Üí88,000 TPA expansion underway)</strong><br />
</li>
<li>Indigenous technology developer in amines manufacturing</li>
</ul></li>
</ul>
<hr />
</div>
<div id="tailwinds-growth-prospects" class="section level6">
<h6>‚úÖ <strong>Tailwinds &amp; Growth Prospects</strong></h6>
<div id="strong-industry-tailwinds" class="section level9">
<p class="heading">1. <strong>Strong Industry Tailwinds</strong></p>
<ul>
<li><strong>Global Amines Market</strong> projected to grow at <strong>~7.8% CAGR</strong> (2024‚Äì2030), reaching <strong>$23.5 billion</strong>.</li>
<li><strong>Pharma</strong> (61%) and <strong>Agrochemicals</strong> (26%) are core end-markets for amines, both structurally growing in India.</li>
<li><strong>Sourcing from India is preferred globally</strong> due to stringent quality standards (REACH, WHO-GMP).</li>
<li><strong>India‚Äôs growing push for import substitution</strong> in specialty chemicals is favorable.</li>
</ul>
</div>
<div id="capacity-expansion-project-commissioning" class="section level9">
<p class="heading">2. <strong>Capacity Expansion &amp; Project Commissioning</strong></p>
<ul>
<li><strong>Methylamines plant (Unit-IV)</strong> successfully commissioned in <strong>Nov 2024</strong> (88,000 TPA capacity ‚Üí cost leadership).</li>
<li><strong>Electronic Grade DMC plant</strong> commissioned in <strong>May 2025</strong> ‚Äì first in India with <strong>15,000 TPA capacity</strong>.</li>
<li><strong>Solar power:</strong> 6 MW AC commissioned in <strong>April 2025</strong>; <strong>20 MW greenfield solar project</strong> underway ‚Äì reduces power costs and <strong>enhances ESG profile</strong>.</li>
<li><strong>Future projects on track:</strong>
<ul>
<li><strong>Dimethyl Ether (DME) ‚Äì 1,00,000 TPA</strong> (FY25-26): LPG substitute; BIS supports 20% blending in LPG.</li>
<li><strong>N-Methyl Morpholine (NMM) ‚Äì 5,000 TPA</strong> (FY25-26): Pharma/oil &amp; gas applications.</li>
<li><strong>Pharma Grade Propylene Glycol (PG)</strong> (FY25-26): For EV batteries and pharmaceuticals.</li>
<li><strong>BSCL Greenfield Project (Rs. 750 Cr expansion):</strong> HCN, NaCN, EDTA, with <strong>Mega Project Status</strong> from Maharashtra govt.</li>
</ul></li>
</ul>
</div>
<div id="first-mover-advantages-high-demand-products" class="section level9">
<p class="heading">3. <strong>First-Mover Advantages &amp; High-Demand Products</strong></p>
<ul>
<li><strong>PVP K-30 &amp; Pharma Grade PG in high demand</strong>; BAL is one of the few domestic manufacturers.</li>
<li><strong>Export opportunities</strong> in electronic-grade DMC and specialty chemicals.</li>
<li><strong>Vertical &amp; horizontal integration</strong> strengthens cost competitiveness and supply chain resilience.</li>
</ul>
</div>
<div id="robust-financial-discipline" class="section level9">
<p class="heading">4. <strong>Robust Financial Discipline</strong></p>
<ul>
<li><strong>Standalone entity is zero-debt</strong>, demonstrating strong internal accruals and self-funding of capex.</li>
<li><strong>Projects funded entirely via internal accruals</strong> ‚Äì low financial risk.</li>
<li><strong>Consistent dividend payout history</strong> ‚Äì FY24: Rs. 11/share; FY25: Rs. 11/share.</li>
</ul>
</div>
<div id="diversified-global-presence" class="section level9">
<p class="heading">5. <strong>Diversified Global Presence</strong></p>
<ul>
<li><strong>Operates in 50+ countries</strong>, with <strong>12.8% revenue from exports</strong>.</li>
<li>Key export markets: <strong>Europe (45‚Äì55% of exports), USA, Japan, South Africa, Middle East</strong>.</li>
<li><strong>REACH compliance</strong> in key chemistry ‚Äì strengthens global competitiveness.</li>
</ul>
</div>
<div id="strong-roce-core-business" class="section level9">
<p class="heading">6. <strong>Strong ROCE Core Business</strong></p>
<ul>
<li><strong>Core chemical business ROCE:</strong> 12% (FY25) vs.¬†consolidated ROCE: 8.6%</li>
<li>Despite lower consolidated ROE due to lagging returns from newer projects (CWP), the <strong>core business remains robust and efficient</strong>.</li>
</ul>
<hr />
</div>
</div>
<div id="headwinds" class="section level6">
<h6>‚ö†Ô∏è <strong>Headwinds</strong></h6>
<div id="near-term-weak-demand" class="section level9">
<p class="heading">1. <strong>Near-Term Weak Demand</strong></p>
<ul>
<li><strong>Pharma &amp; Agrochemical sectors witnessing lower offtake</strong> due to <strong>geopolitical tensions and global demand softness</strong>.</li>
<li>New capacities (e.g.¬†DME, PG Pharma Grade) are ramping up but <strong>not contributing meaningfully to revenue yet</strong>.</li>
</ul>
</div>
<div id="margin-pressure" class="section level9">
<p class="heading">2. <strong>Margin Pressure</strong></p>
<ul>
<li><strong>Consolidated PAT Margin:</strong> 11% (Q2FY26), down from 12% in Q2FY25.</li>
<li><strong>Standalone PAT Margin:</strong> 10% (Q2FY26) from 12%, reflecting cost pressures and muted volumes.</li>
<li><strong>Q-o-Q volume decline:</strong> 26,165 MT (Q2FY26) vs.¬†27,570 MT (Q1FY26) ‚Äì driven by lower offtake.</li>
</ul>
</div>
<div id="revenue-gradual-decline" class="section level9">
<p class="heading">3. <strong>Revenue Gradual Decline</strong></p>
<ul>
<li><strong>Standalone Revenue:</strong> Down 3% YoY in Q2 and H1FY26.</li>
<li><strong>Consolidated Revenue:</strong> 2% YoY fall in Q2; 5% fall in H1.</li>
<li>Indicates <strong>softening near-term demand</strong> or pricing challenges.</li>
</ul>
</div>
<div id="delayed-contributions-from-cwp" class="section level9">
<p class="heading">4. <strong>Delayed Contributions from CWP</strong></p>
<ul>
<li><strong>Capital Work-in-Progress (CWP):</strong> Rising sharply ‚Äì <strong>Rs. 339 Cr (Consolidated, Sep-25)</strong> from Rs. 234 Cr (Mar-25).</li>
<li>Projects in process (BSCL Expansion, Solar, DME, NMM) are <strong>not yet revenue-generating</strong> and are weighing on ROCE.</li>
</ul>
</div>
<div id="cash-flow-pressure" class="section level9">
<p class="heading">5. <strong>Cash Flow Pressure</strong></p>
<ul>
<li><strong>Consolidated Cash Flow from Operations:</strong> ‚Çπ22.2 Cr (9 months FY26) vs.¬†‚Çπ195.3 Cr in YoY period ‚Äì <strong>sharp decline</strong> due to working capital increase.</li>
<li><strong>Net decrease in cash</strong>: ‚Çπ109.8 Cr in 6 months ‚Üí cash position (consolidated) dropped from ‚Çπ148.9 Cr (Mar-25) to ‚Çπ39.1 Cr (Sep-25).</li>
<li><strong>Significant capex outflows</strong> (Investing - ‚Çπ115 Cr) funded by internal accruals, but pressure is evident.</li>
</ul>
<hr />
</div>
</div>
<div id="key-risks" class="section level6">
<h6>‚ö†Ô∏è <strong>Key Risks</strong></h6>
<div id="regulatory-legal-risk" class="section level9">
<p class="heading">1. <strong>Regulatory &amp; Legal Risk</strong></p>
<ul>
<li><strong>Summons from a Gujarat court</strong> under the <strong>Drugs &amp; Cosmetics Act, 1940</strong> (Nov 25, 2025).
<ul>
<li>Alleged violation under Sections 16(1)(a), 18(a)(i), 34, etc.</li>
<li>Company asserts <strong>no material financial/operational impact</strong>, but ongoing litigation could lead to reputational or compliance risks.</li>
<li>Risk of regulatory penalties, especially if linked to product quality.</li>
</ul></li>
</ul>
</div>
<div id="commodity-raw-material-price-volatility" class="section level9">
<p class="heading">2. <strong>Commodity &amp; Raw Material Price Volatility</strong></p>
<ul>
<li>Major inputs: <strong>Ammonia, Methanol, Denatured Ethyl Alcohol</strong>
<ul>
<li><strong>Methanol</strong> is mostly <strong>imported from Middle East</strong> ‚Üí exposed to <strong>global price shocks, logistics disruptions, FX volatility</strong>.</li>
<li>EBITDA margin at 19% in Q2FY26 ‚Äì flat Q-o-Q but down from 20% a year ago ‚Äì suggests cost pressure.</li>
</ul></li>
</ul>
</div>
<div id="execution-timing-risk-in-expansion-projects" class="section level9">
<p class="heading">3. <strong>Execution &amp; Timing Risk in Expansion Projects</strong></p>
<ul>
<li><strong>Multiple new projects</strong> (DME, PG Pharma Grade, BSCL expansion) are under execution.</li>
<li>Delays could result in <strong>missed revenue targets</strong> and <strong>prolonged capital drain</strong>.</li>
<li>However, company emphasizes <strong>all projects are on internal funding and schedule</strong> ‚Äì mitigating factor.</li>
</ul>
</div>
<div id="liquidity-risk-from-falling-cash-reserves" class="section level9">
<p class="heading">4. <strong>Liquidity Risk from Falling Cash Reserves</strong></p>
<ul>
<li><strong>Consolidated cash balances fell by ~73% (‚Çπ149 Cr ‚Üí ‚Çπ39 Cr)</strong> in 6 months.</li>
<li>While the company is debt-free at standalone, <strong>consolidated borrowings increased to ‚Çπ31.1 Cr</strong> (Sep-25) from zero earlier ‚Üí short-term financing for capex?</li>
</ul>
</div>
<div id="hotel-business-drag" class="section level9">
<p class="heading">5. <strong>Hotel Business Drag</strong></p>
<ul>
<li>The 5-star hotel contributes <strong>only 2.3% of revenue</strong>.</li>
<li><strong>Loss-making or marginally profitable</strong>?
<ul>
<li>Standalone EBIT margin: 14% (Q2FY26) vs.¬†previous 17% ‚Äì may reflect poor performance of non-core assets.</li>
<li><strong>Positive occupancy (70‚Äì75%)</strong>, but ROE drag due to large initial investment (‚Çπ110 Cr).</li>
</ul></li>
</ul>
</div>
<div id="fx-export-risk" class="section level9">
<p class="heading">6. <strong>FX &amp; Export Risk</strong></p>
<ul>
<li>12.8% revenue from exports.</li>
<li>Exposure to <strong>currency fluctuations</strong>, EU regulations, and trade disruptions in current global environment.</li>
</ul>
<hr />
</div>
</div>
<div id="financial-snapshot-q2-h1fy26-vs.-prior-periods" class="section level6">
<h6>üìà Financial Snapshot: Q2 &amp; H1FY26 (vs.¬†Prior Periods)</h6>
<table>
<colgroup>
<col width="7%" />
<col width="18%" />
<col width="18%" />
<col width="8%" />
<col width="18%" />
<col width="18%" />
<col width="8%" />
</colgroup>
<thead>
<tr class="header">
<th>Metric</th>
<th>Q2FY26 (Consol)</th>
<th>Q2FY25 (Consol)</th>
<th>YoY Chg</th>
<th>H1FY26 (Consol)</th>
<th>H1FY25 (Consol)</th>
<th>YoY Chg</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Revenue (Cr)</strong></td>
<td>348</td>
<td>356</td>
<td>-2.2%</td>
<td>715</td>
<td>749</td>
<td>-4.5%</td>
</tr>
<tr class="even">
<td><strong>EBITDA (Cr)</strong></td>
<td>67</td>
<td>70</td>
<td>-4.3%</td>
<td>131</td>
<td>144</td>
<td>-9%</td>
</tr>
<tr class="odd">
<td><strong>PAT (Cr)</strong></td>
<td>37</td>
<td>41</td>
<td>-9.8%</td>
<td>74</td>
<td>87</td>
<td>-15%</td>
</tr>
<tr class="even">
<td><strong>EBITDA Margin</strong></td>
<td>19%</td>
<td>20%</td>
<td>-100 bps</td>
<td>18%</td>
<td>19%</td>
<td>-100 bps</td>
</tr>
<tr class="odd">
<td><strong>PAT Margin</strong></td>
<td>11%</td>
<td>12%</td>
<td>-100 bps</td>
<td>10%</td>
<td>12%</td>
<td>-200 bps</td>
</tr>
</tbody>
</table>
<blockquote>
<p><strong>Note:</strong> Despite a marginal dip in revenue, <strong>EBITDA margin improved from 17% (Q1FY26)</strong> due to better cost control and scale.</p>
</blockquote>
<hr />
</div>
<div id="outlook-strategic-direction" class="section level6">
<h6>üéØ Outlook &amp; Strategic Direction</h6>
<ul>
<li><strong>Near-Term (Q3‚ÄìQ4FY26):</strong> Gradual recovery expected as new plants stabilize and global demand recovers.</li>
<li><strong>Medium to Long Term:</strong>
<ul>
<li><strong>Scalable growth</strong> via high-margin specialty products (e.g., NMM, PG Pharma, DMC EL Grade).</li>
<li><strong>Cost advantage</strong> from integrated, tech-upgraded Methylamines base.</li>
<li><strong>EV battery</strong> and <strong>renewables (solar power)</strong> positioning align with future chemical trends.</li>
</ul></li>
</ul>
<hr />
</div>
<div id="summary-investment-thesis" class="section level6">
<h6>‚úÖ Summary: Investment Thesis</h6>
<table>
<colgroup>
<col width="36%" />
<col width="63%" />
</colgroup>
<thead>
<tr class="header">
<th>Factor</th>
<th>Assessment</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Growth Potential</strong></td>
<td>High ‚Äì fueled by capacity expansions, new product launches, and import substitution.</td>
</tr>
<tr class="even">
<td><strong>Competitive Edge</strong></td>
<td>Strong ‚Äì market leadership, indigenous tech, zero debt, ESG compliance.</td>
</tr>
<tr class="odd">
<td><strong>Financial Health (Standalone)</strong></td>
<td>Excellent ‚Äì zero debt, healthy margins, dividend payor.</td>
</tr>
<tr class="even">
<td><strong>Consolidated Performance</strong></td>
<td>Pressured ‚Äì weak near-term margins, lower cash flow, high CWP.</td>
</tr>
<tr class="odd">
<td><strong>Tailwinds</strong></td>
<td>1. Domestic manufacturing push (PLI, import substitution)<br>2. Pharma/agrochem demand cycle improving<br>3. Global green supply chain shift</td>
</tr>
<tr class="even">
<td><strong>Headwinds</strong></td>
<td>1. Global demand softness<br>2. High capex burden<br>3. Legacy product saturation</td>
</tr>
<tr class="odd">
<td><strong>Key Risks</strong></td>
<td>1. Regulatory scrutiny (Drugs Act summons)<br>2. Commodity price volatility<br>3. Liquidity constraints due to capital intensity</td>
</tr>
</tbody>
</table>
<hr />
<div id="final-verdict" class="section level9">
<p class="heading">üìå Final Verdict:</p>
<p><strong>Balaji Amines is at an inflection point.</strong> Despite <strong>near-term headwinds</strong> in demand and margins, the company is <strong>strategically investing</strong> in high-growth, high-margin segments. Its <strong>zero-debt standalone structure</strong>, <strong>technological edge</strong>, and <strong>large unmet domestic demand for specialty chemicals</strong> provide a strong long-term foundation.</p>
<blockquote>
<p><strong>Bull Case:</strong> Successful ramp-up of DME, NMM, PG Pharma, and BSCL projects could drive <strong>top-line growth and margin expansion</strong>, delivering <strong>15‚Äì20% EPS CAGR</strong> from FY27 onward.</p>
</blockquote>
<blockquote>
<p><strong>Bear Case:</strong> Prolonged weak offtake, cost overruns, or legal risks could delay returns from capex, <strong>keeping ROE low</strong> and <strong>dividend sustainability under pressure</strong>.</p>
</blockquote>
<hr />
</div>
<div id="recommendation" class="section level9">
<p class="heading">üì¢ Recommendation:</p>
<ul>
<li><strong>For Long-Term Investors:</strong> Attractive entry opportunity during weakness (e.g., if stock corrects below book value).</li>
<li><strong>For Traders:</strong> Monitor Q3FY26 commentary for signs of demand recovery and capex monetization.</li>
<li><strong>Catalyst Watch:</strong> Commissioning of DME (FY25-26), BSCL Phase-I (Dec-26), and EV-grade DMC ramp-up.</li>
</ul>
<hr />
<p>üîç <strong>Final Note:</strong><br />
While current results show deceleration, the <strong>underlying strategy and capital allocation are sound</strong>. The <strong>investment story hinges on project execution</strong>, which Balaji has shown <strong>consistent capability</strong> in delivering. <strong>Patience required</strong> ‚Äì this is a <strong>multi-year transformation story</strong> with potential for <strong>market leadership in India‚Äôs specialty chem space</strong>.</p>
</div>
</div>
</div>
</div>

&nbsp;
&nbsp;
<hr />
<p style="text-align: center;">Copyright &copy; 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.</p>
<p style="text-align: center;"><a href="https://github.com/stockviz/reports/issues">&#x1F41E;</a></p>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
